Phase II Trial of Reduced Intensity Conditioning (RIC) and Allogeneic Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Event Free Survival
Number of subjects surviving with no events at 180 days post transplantation (Day 0).
180 days
Yes
Mary J. Laughlin, MD
Principal Investigator
University of Virginia
United States: Food and Drug Administration
15954 UCB-2011
NCT01622556
January 2012
January 2017
Name | Location |
---|---|
University of Virginia | Charlottesville, Virginia 22908 |